Skip to Content

Posts tagged with "Drug Prices"

  • Business and Markets

    GlaxoSmithKline’s New Strategy, Defended

    GlaxoSmithKline’s Moncef Slaoui has an interview in the Philadelphia Inquirer, and he’s responding to critics of the company’s strategy (and to rumors about it): Slaoui suggested some reality for pharma cheerleaders: First, most Americans think drug prices are way too high and sooner or later the bottom will fall out from those fi… Read More
  • Drug Prices

    The Drug Abacus

    How much should drugs cost? That question can be answered in a lot of different ways, and at many levels of economic literacy. But the Wall Street Journal is reporting on a new comparison tool from a group at Sloan-Kettering, the “Drug Abacus“. As you will have already guessed, under many plausible assumptions (such as… Read More
  • Business and Markets

    Piling On Andrew Witty

    To go along with the recent calls for Andrew Witty to step down at GSK, here’s John LaMattina wondering if he’s the right guy for the job as well: . . .the bigger issue with Witty’s stance is the direction that he is taking GSK. His company has a long and proud history of delivering… Read More
  • Business and Markets

    Market Exclusivity Is Sometimes Too Much

    Readers might remember a small company called Catalyst Pharmaceuticals, who have had a business plan that goes something like this: take the known small molecule that’s used for the rare disease Lambert-Eaton Myasthenic Syndrome LEMS, 3,4-diaminopyridine. Rebrand it as “Firdapse”, and do the clinical work needed to get it official… Read More
  • Drug Prices

    More Price Hikes on Obscure Medication

    Get ready for some twists and turns here. I wrote back in September about the business model of Retrophin, a company whose plans (at least for the foreseeable future) were to find small-market drugs, buy them from their obscure producers, and then raise their prices into geosynchronous orbit. That particular story blew up in unforeseen… Read More
  • Drug Prices

    Catalyst Pharmaceuticals and Their Disgusting Business Strategy

    OK, this seems to be a new business model, damn it all. I wrote here recently about the huge price increase of Thiola (tiopronin) by a small company called Retrophin. Now, as I wrote about here last year, another small company called Catalyst Pharmaceuticals is preparing to jack up the price of Firdapse (3,4-diaminopyridine) for… Read More
  • Business and Markets

    Thiola, Retrophin, Martin Shkrell, Reddit, and More

    Well, it was not a dull evening around the In the Pipeline headquarters last night. I submitted a link to Reddit for my post yesterday about Retrophin and Thiola, and that blew up onto that site’s front page. The Corante server melted under the impact, which isn’t too surprising, since it’s struggling at the best… Read More
  • Business and Markets

    The Most Unconscionable Drug Price Hike I Have Yet Seen

    There’s a drug called Thiola (tiopronin) that most people have never heard of. It’s on my list of “smaller than aspirin” drugs, and I’d never heard of it until I put that one together. But thanks to a little company called Retrophin, we all get to hear about it now. It’s used to treat cystinuria… Read More
  • Drug Prices

    BioCentury on the Coming Drug Pricing Crisis

    I always enjoy BioCentury‘s “Back to School” issue this time of year, and this time they’re being more outspoken than usual. (That link is free access). The topic is pricing: Last year, (we) argued biopharma companies can no longer assume the market will support premium pricing, even for drugs that deliver meaningful and mea… Read More
  • Cancer

    Incomprehensible Drug Prices? Think Again.

    There’s a post by Peter Bach, of the Center for Health Policy and Outcomes, that’s been getting a lot of attention the last few days. It’s called “Unpronounceable Drugs, Incomprehensible Prices”, and you know what it says. No, really, you do, even if you haven’t seen it. Too high, unconscionable, market can’… Read More